Public trial registry of the CCC-Munich

Trial ACE-536-MDS-001

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
ACE-536-MDS-001
World
Full title
:

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions,

World
NCT number
:
World
Responsible organization
:
3. Med 3. Med Ismaninger Str. 22 81675 München Germany Tum
Indications
Classification Code Description
- D46.9 Myelodysplastisches Syndrom, nicht näher bezeichnet
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Positive
World
Institutional review board - vote date
:
2016-04-07
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy
:

Chemo

Participants
Function Prename Surname Organization
World Responsible contact Katharina Götze Keine Organisationseinheit angegeben Magnifier